ID   BXA1_CLOBO              Reviewed;        1296 AA.
AC   P0DPI0; A5HZZ9; A7G1U9; P01561; P10845; P18639;
DT   18-JUL-2018, integrated into UniProtKB/Swiss-Prot.
DT   18-JUL-2018, sequence version 1.
DT   03-AUG-2022, entry version 25.
DE   RecName: Full=Botulinum neurotoxin type A;
DE            Short=BoNT/A;
DE   AltName: Full=Bontoxilysin-A;
DE            Short=BOTOX;
DE   AltName: Full=Botulinum neurotoxin type A1;
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin A light chain;
DE              Short=LC;
DE              EC=3.4.24.69 {ECO:0000269|PubMed:8243676};
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin A heavy chain;
DE              Short=HC;
DE   Flags: Precursor;
GN   Name=botA {ECO:0000303|PubMed:2185020};
GN   Synonyms=atx {ECO:0000303|PubMed:8521962}, bonT
GN   {ECO:0000303|PubMed:8863443};
OS   Clostridium botulinum.
OC   Bacteria; Firmicutes; Clostridia; Eubacteriales; Clostridiaceae;
OC   Clostridium.
OX   NCBI_TaxID=1491;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=NCTC 2916 / Type A;
RX   PubMed=2185020; DOI=10.1111/j.1432-1033.1990.tb15461.x;
RA   Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.-J., Shone C.C.,
RA   Atkinson T., Melling J., Minton N.P.;
RT   "The complete amino acid sequence of the Clostridium botulinum type A
RT   neurotoxin, deduced by nucleotide sequence analysis of the encoding gene.";
RL   Eur. J. Biochem. 189:73-81(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=62A / Type A;
RX   PubMed=2160960; DOI=10.1016/s0021-9258(19)38824-6;
RA   Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H.;
RT   "The complete sequence of botulinum neurotoxin type A and comparison with
RT   other clostridial neurotoxins.";
RL   J. Biol. Chem. 265:9153-9158(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-66.
RC   STRAIN=62A / Type A;
RX   PubMed=8863443; DOI=10.1099/00207713-46-4-1105;
RA   East A.K., Bhandari M., Stacey J.M., Campbell K.D., Collins M.D.;
RT   "Organization and phylogenetic interrelationships of genes encoding
RT   components of the botulinum toxin complex in proteolytic Clostridium
RT   botulinum types A, B, and F: evidence of chimeric sequences in the gene
RT   encoding the nontoxic nonhemagglutinin component.";
RL   Int. J. Syst. Bacteriol. 46:1105-1112(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19.
RC   STRAIN=NIH / Type A;
RX   PubMed=8521962; DOI=10.1016/0014-5793(95)01241-5;
RA   Fujita R., Fujinaga Y., Inoue K., Nakajima H., Kumon H., Oguma K.;
RT   "Molecular characterization of two forms of nontoxic-nonhemagglutinin
RT   components of Clostridium botulinum type A progenitor toxins.";
RL   FEBS Lett. 376:41-44(1995).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-18 AND 449-458, AND SUBCELLULAR LOCATION (BOTULINUM
RP   NEUROTOXIN A LIGHT CHAIN AND BOTULINUM NEUROTOXIN A HEAVY CHAIN).
RC   STRAIN=Type A;
RX   PubMed=6370252; DOI=10.1016/0006-291x(84)90858-1;
RA   Schmidt J.J., Sartymoorthy V., Dasgupta B.R.;
RT   "Partial amino acid sequence of the heavy and light chains of botulinum
RT   neurotoxin type A.";
RL   Biochem. Biophys. Res. Commun. 119:900-904(1984).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-47.
RA   Dasgupta B.R., Foley J., Niece R.;
RT   "Partial sequence of the light chain of botulinum neurotoxin type A.";
RL   Biochemistry 26:4162-4162(1987).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-6 AND 445-457, AND PROCESSING.
RC   STRAIN=Type A;
RX   PubMed=2126206; DOI=10.1016/0300-9084(90)90048-l;
RA   Dasgupta B.R., Dekleva M.L.;
RT   "Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and
RT   around the nicking site.";
RL   Biochimie 72:661-664(1990).
RN   [8]
RP   PROTEIN SEQUENCE OF 251-257; 267-273 AND 420-448, COFACTOR, AND PROTEOLYTIC
RP   CLEAVAGE.
RX   PubMed=11565902; DOI=10.1023/a:1010952025677;
RA   Ahmed S.A., Byrne M.P., Jensen M., Hines H.B., Brueggemann E., Smith L.A.;
RT   "Enzymatic autocatalysis of botulinum A neurotoxin light chain.";
RL   J. Protein Chem. 20:221-231(2001).
RN   [9]
RP   PROTEIN SEQUENCE OF 449-483.
RC   STRAIN=NCTC 2916 / Type A;
RX   PubMed=3896784; DOI=10.1111/j.1432-1033.1985.tb09070.x;
RA   Shone C.C., Hambleton P., Melling J.;
RT   "Inactivation of Clostridium botulinum type A neurotoxin by trypsin and
RT   purification of two tryptic fragments. Proteolytic action near the COOH-
RT   terminus of the heavy subunit destroys toxin-binding activity.";
RL   Eur. J. Biochem. 151:75-82(1985).
RN   [10]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE A).
RC   STRAIN=4587 / Type A;
RX   PubMed=15394302; DOI=10.1113/jphysiol.1949.sp004364;
RA   Burgen A.S., Dickens F., Zatman L.J.;
RT   "The action of botulinum toxin on the neuro-muscular junction.";
RL   J. Physiol. (Lond.) 109:10-24(1949).
RN   [11]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN TYPE A AND BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND
RP   ACTIVITY REGULATION.
RC   STRAIN=Type A;
RX   PubMed=6694738; DOI=10.1038/307457a0;
RA   Dolly J.O., Black J., Williams R.S., Melling J.;
RT   "Acceptors for botulinum neurotoxin reside on motor nerve terminals and
RT   mediate its internalization.";
RL   Nature 307:457-460(1984).
RN   [12]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND DOMAIN.
RC   STRAIN=Type A;
RX   PubMed=2446925; DOI=10.1016/0014-5793(87)80562-8;
RA   Blaustein R.O., Germann W.J., Finkelstein A., DasGupta B.R.;
RT   "The N-terminal half of the heavy chain of botulinum type A neurotoxin
RT   forms channels in planar phospholipid bilayers.";
RL   FEBS Lett. 226:115-120(1987).
RN   [13]
RP   IDENTIFICATION AS A ZINC-BINDING PROTEIN, AND COFACTOR.
RC   STRAIN=Type A;
RX   PubMed=1429690; DOI=10.1016/s0021-9258(18)35863-0;
RA   Schiavo G., Rossetto O., Santucci A., Dasgupta B.R., Montecucco C.;
RT   "Botulinum neurotoxins are zinc proteins.";
RL   J. Biol. Chem. 267:23479-23483(1992).
RN   [14]
RP   HOST RANGE, AND EPIDEMIOLOGY.
RX   PubMed=1431246; DOI=10.1093/infdis/166.6.1281;
RA   Woodruff B.A., Griffin P.M., McCroskey L.M., Smart J.F., Wainwright R.B.,
RA   Bryant R.G., Hutwagner L.C., Hatheway C.L.;
RT   "Clinical and laboratory comparison of botulism from toxin types A, B, and
RT   E in the United States, 1975-1988.";
RL   J. Infect. Dis. 166:1281-1286(1992).
RN   [15]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN), IDENTIFICATION OF SUBSTRATE,
RP   CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN A LIGHT
RP   CHAIN).
RC   STRAIN=Type A;
RX   PubMed=8243676; DOI=10.1016/0014-5793(93)80448-4;
RA   Schiavo G., Santtuci A., Dasgupta B.R., Mehta P.P., Jontes J.,
RA   Benfenati F., Wilson M.C., Montecucco C.;
RT   "Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-
RT   terminal peptide bonds.";
RL   FEBS Lett. 335:99-103(1993).
RN   [16]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE A AND BOTULINUM NEUROTOXIN A LIGHT
RP   CHAIN), CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN A LIGHT CHAIN), DOMAIN, AND MUTAGENESIS OF HIS-227.
RC   STRAIN=63A / Type A;
RX   PubMed=7578132; DOI=10.1021/bi00046a025;
RA   Zhou L., de Paiva A., Liu D., Aoki R., Dolly J.O.;
RT   "Expression and purification of the light chain of botulinum neurotoxin A:
RT   a single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after
RT   reconstitution with the heavy chain.";
RL   Biochemistry 34:15175-15181(1995).
RN   [17]
RP   SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN TYPE A), AND INDUCTION.
RC   STRAIN=62A / Type A;
RX   PubMed=7592120; DOI=10.1111/j.1365-2672.1995.tb03135.x;
RA   Call J.E., Cooke P.H., Miller A.J.;
RT   "In situ characterization of Clostridium botulinum neurotoxin synthesis and
RT   export.";
RL   J. Appl. Bacteriol. 79:257-263(1995).
RN   [18]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN A HEAVY CHAIN).
RC   STRAIN=62A / P64 / Type A;
RX   PubMed=10413679; DOI=10.1242/jcs.112.16.2715;
RA   Lalli G., Herreros J., Osborne S.L., Montecucco C., Rossetto O.,
RA   Schiavo G.;
RT   "Functional characterisation of tetanus and botulinum neurotoxins binding
RT   domains.";
RL   J. Cell Sci. 112:2715-2724(1999).
RN   [19]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN), SUBSTRATE SPECIFICITY,
RP   CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN A LIGHT
RP   CHAIN).
RC   STRAIN=62A / P64 / Type A;
RX   PubMed=9886085; DOI=10.1046/j.1471-4159.1999.0720327.x;
RA   Vaidyanathan V.V., Yoshino K., Jahnz M., Doerries C., Bade S.,
RA   Nauenburg S., Niemann H., Binz T.;
RT   "Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E:
RT   domains and amino acid residues controlling the formation of enzyme-
RT   substrate complexes and cleavage.";
RL   J. Neurochem. 72:327-337(1999).
RN   [20]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN), ACTIVE SITE, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF GLU-224.
RC   STRAIN=Type A;
RX   PubMed=10694409; DOI=10.1021/bi992321x;
RA   Li L., Binz T., Niemann H., Singh B.R.;
RT   "Probing the mechanistic role of glutamate residue in the zinc-binding
RT   motif of type A botulinum neurotoxin light chain.";
RL   Biochemistry 39:2399-2405(2000).
RN   [21]
RP   BIOTECHNOLOGY.
RC   STRAIN=NCTC 2916 / Type A;
RX   PubMed=10768948; DOI=10.1128/iai.68.5.2587-2593.2000;
RA   Chaddock J.A., Purkiss J.R., Friis L.M., Broadbridge J.D., Duggan M.J.,
RA   Fooks S.J., Shone C.C., Quinn C.P., Foster K.A.;
RT   "Inhibition of vesicular secretion in both neuronal and nonneuronal cells
RT   by a retargeted endopeptidase derivative of Clostridium botulinum
RT   neurotoxin type A.";
RL   Infect. Immun. 68:2587-2593(2000).
RN   [22]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN), COFACTOR, AND MUTAGENESIS OF
RP   GLU-262; PHE-266 AND TYR-366.
RC   STRAIN=P64 / Type A;
RX   PubMed=11700044; DOI=10.1006/bbrc.2001.5911;
RA   Rigoni M., Caccin P., Johnson E.A., Montecucco C., Rossetto O.;
RT   "Site-directed mutagenesis identifies active-site residues of the light
RT   chain of botulinum neurotoxin type A.";
RL   Biochem. Biophys. Res. Commun. 288:1231-1237(2001).
RN   [23]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN), BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF GLU-351; ARG-363 AND TYR-366.
RC   STRAIN=62A / P64 / Type A;
RX   PubMed=11827515; DOI=10.1021/bi0157969;
RA   Binz T., Bade S., Rummel A., Kollewe A., Alves J.;
RT   "Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are
RT   involved in transition state stabilization.";
RL   Biochemistry 41:1717-1723(2002).
RN   [24]
RP   REQUIREMENT FOR GANGLIOSIDES FOR ACTIVITY (BOTULINUM NEUROTOXIN TYPE A).
RC   STRAIN=Type A;
RX   PubMed=12089155; DOI=10.1074/jbc.m205258200;
RA   Yowler B.C., Kensinger R.D., Schengrund C.L.;
RT   "Botulinum neurotoxin A activity is dependent upon the presence of specific
RT   gangliosides in neuroblastoma cells expressing synaptotagmin I.";
RL   J. Biol. Chem. 277:32815-32819(2002).
RN   [25]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), GANGLIOSIDE-BINDING
RP   (BOTULINUM NEUROTOXIN A HEAVY CHAIN), MUTAGENESIS OF GLU-1203; HIS-1253;
RP   SER-1264; TRP-1266 AND TYR-1267, AND LIPID-BINDING.
RC   STRAIN=62A / Type A;
RX   PubMed=14731268; DOI=10.1046/j.1365-2958.2003.03872.x;
RA   Rummel A., Mahrhold S., Bigalke H., Binz T.;
RT   "The HCC-domain of botulinum neurotoxins A and B exhibits a singular
RT   ganglioside binding site displaying serotype specific carbohydrate
RT   interaction.";
RL   Mol. Microbiol. 51:631-643(2004).
RN   [26]
RP   IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE A AND BOTULINUM
RP   NEUROTOXIN A HEAVY CHAIN), AND INTERACTION WITH HOST SV2C.
RC   STRAIN=Type A;
RX   PubMed=16545378; DOI=10.1016/j.febslet.2006.02.074;
RA   Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T.;
RT   "The synaptic vesicle protein 2C mediates the uptake of botulinum
RT   neurotoxin A into phrenic nerves.";
RL   FEBS Lett. 580:2011-2014(2006).
RN   [27]
RP   IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE A), AND
RP   INTERACTION WITH HOST SV2 PROTEINS.
RC   STRAIN=Type A;
RX   PubMed=16543415; DOI=10.1126/science.1123654;
RA   Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R.;
RT   "SV2 is the protein receptor for botulinum neurotoxin A.";
RL   Science 312:592-596(2006).
RN   [28]
RP   FUNCTION (BOTULINUM NEUROTOXIN A LIGHT AND HEAVY CHAIN), DOMAIN, AND
RP   DISULFIDE BOND.
RX   PubMed=17666397; DOI=10.1074/jbc.m703619200;
RA   Fischer A., Montal M.;
RT   "Crucial role of the disulfide bridge between botulinum neurotoxin light
RT   and heavy chains in protease translocation across membranes.";
RL   J. Biol. Chem. 282:29604-29611(2007).
RN   [29]
RP   DISCUSSION OF BELT FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND
RP   DOMAIN.
RX   PubMed=17907800; DOI=10.1371/journal.ppat.0030113;
RA   Brunger A.T., Breidenbach M.A., Jin R., Fischer A., Santos J.S., Montal M.;
RT   "Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for
RT   the light chain.";
RL   PLoS Pathog. 3:1191-1194(2007).
RN   [30]
RP   IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE A), AND
RP   INTERACTION WITH HOST SV2 PROTEINS.
RC   STRAIN=Type A;
RX   PubMed=18815274; DOI=10.1091/mbc.e08-07-0765;
RA   Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R.;
RT   "Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E
RT   into neurons.";
RL   Mol. Biol. Cell 19:5226-5237(2008).
RN   [31]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND DOMAIN.
RC   STRAIN=Type A;
RX   PubMed=19096517; DOI=10.1371/journal.ppat.1000245;
RA   Fischer A., Mushrush D.J., Lacy D.B., Montal M.;
RT   "Botulinum neurotoxin devoid of receptor binding domain translocates active
RT   protease.";
RL   PLoS Pathog. 4:E1000245-E1000245(2008).
RN   [32]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), DOMAIN, AND
RP   PHOSPHATIDYLINOSITOL-BINDING.
RC   STRAIN=Type A;
RX   PubMed=19161982; DOI=10.1016/j.bbrc.2009.01.037;
RA   Muraro L., Tosatto S., Motterlini L., Rossetto O., Montecucco C.;
RT   "The N-terminal half of the receptor domain of botulinum neurotoxin A binds
RT   to microdomains of the plasma membrane.";
RL   Biochem. Biophys. Res. Commun. 380:76-80(2009).
RN   [33]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE A), FUNCTION (BOTULINUM NEUROTOXIN A
RP   HEAVY CHAIN), INTERACTION WITH HOST SV2 PROTEINS, AND MUTAGENESIS OF
RP   TRP-1266.
RX   PubMed=19650874; DOI=10.1111/j.1471-4159.2009.06298.x;
RA   Rummel A., Haefner K., Mahrhold S., Darashchonak N., Holt M., Jahn R.,
RA   Beermann S., Karnath T., Bigalke H., Binz T.;
RT   "Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding
RT   site prior to stimulation-dependent uptake with botulinum neurotoxin F
RT   utilising the three isoforms of SV2 as second receptor.";
RL   J. Neurochem. 110:1942-1954(2009).
RN   [34]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE A), AND SUBCELLULAR LOCATION (BOTULINUM
RP   NEUROTOXIN A HEAVY CHAIN).
RC   STRAIN=Type A;
RX   PubMed=21632541; DOI=10.1074/jbc.m111.254086;
RA   Kroken A.R., Karalewitz A.P., Fu Z., Kim J.J., Barbieri J.T.;
RT   "Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into
RT   neurons.";
RL   J. Biol. Chem. 286:26828-26837(2011).
RN   [35]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE A), SUBCELLULAR LOCATION (BOTULINUM
RP   NEUROTOXIN A HEAVY CHAIN), AND ACTIVITY REGULATION.
RX   PubMed=21832053; DOI=10.1074/jbc.m111.283879;
RA   Harper C.B., Martin S., Nguyen T.H., Daniels S.J., Lavidis N.A.,
RA   Popoff M.R., Hadzic G., Mariana A., Chau N., McCluskey A., Robinson P.J.,
RA   Meunier F.A.;
RT   "Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in
RT   neurons and delays botulism.";
RL   J. Biol. Chem. 286:35966-35976(2011).
RN   [36]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), TRANSCYTOSIS ACROSS HOST
RP   CELLS, BIOTECHNOLOGY, AND MUTAGENESIS OF HIS-1253; 1266-TRP-TYR-1267;
RP   TRP-1266 AND TYR-1267.
RC   STRAIN=62A / Type A;
RX   PubMed=21106906; DOI=10.1124/jpet.110.175018;
RA   Elias M., Al-Saleem F., Ancharski D.M., Singh A., Nasser Z., Olson R.M.,
RA   Simpson L.L.;
RT   "Evidence that botulinum toxin receptors on epithelial cells and neuronal
RT   cells are not identical: implications for development of a non-neurotropic
RT   vaccine.";
RL   J. Pharmacol. Exp. Ther. 336:605-612(2011).
RN   [37]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND DOMAIN.
RC   STRAIN=Type A;
RX   PubMed=22158863; DOI=10.1074/jbc.c111.319400;
RA   Fischer A., Sambashivan S., Brunger A.T., Montal M.;
RT   "Beltless translocation domain of botulinum neurotoxin A embodies a minimum
RT   ion-conductive channel.";
RL   J. Biol. Chem. 287:1657-1661(2012).
RN   [38]
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN A HEAVY CHAIN).
RX   PubMed=23471747; DOI=10.1007/s12035-013-8423-9;
RA   Colasante C., Rossetto O., Morbiato L., Pirazzini M., Molgo J.,
RA   Montecucco C.;
RT   "Botulinum neurotoxin type A is internalized and translocated from small
RT   synaptic vesicles at the neuromuscular junction.";
RL   Mol. Neurobiol. 48:120-127(2013).
RN   [39]
RP   POSSIBLE IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE A).
RC   STRAIN=Type A;
RX   PubMed=23696738; DOI=10.1371/journal.ppat.1003369;
RA   Jacky B.P., Garay P.E., Dupuy J., Nelson J.B., Cai B., Molina Y., Wang J.,
RA   Steward L.E., Broide R.S., Francis J., Aoki K.R., Stevens R.C.,
RA   Fernandez-Salas E.;
RT   "Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein
RT   receptor for botulinum neurotoxin serotype A (BoNT/A).";
RL   PLoS Pathog. 9:E1003369-E1003369(2013).
RN   [40]
RP   RECOGNITION OF RECEPTOR (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND SUBUNIT.
RC   STRAIN=62A / Type A;
RX   PubMed=27313224; DOI=10.1042/bcj20160439;
RA   Mahrhold S., Bergstroem T., Stern D., Dorner B.G., Aastot C., Rummel A.;
RT   "Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C
RT   mediates high affinity binding to botulinum neurotoxin serotype A1.";
RL   Biochem. J. 473:2645-2654(2016).
RN   [41]
RP   UBIQUITINATION (BOTULINUM NEUROTOXIN A LIGHT CHAIN).
RX   PubMed=28584101; DOI=10.1073/pnas.1621076114;
RA   Tsai Y.C., Kotiya A., Kiris E., Yang M., Bavari S., Tessarollo L.,
RA   Oyler G.A., Weissman A.M.;
RT   "Deubiquitinating enzyme VCIP135 dictates the duration of botulinum
RT   neurotoxin type A intoxication.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:E5158-E5166(2017).
RN   [42]
RP   REVIEW.
RX   PubMed=23518040; DOI=10.1016/j.toxicon.2013.02.014;
RA   Simpson L.;
RT   "The life history of a botulinum toxin molecule.";
RL   Toxicon 68:40-59(2013).
RN   [43]
RP   REVIEW.
RX   PubMed=28356439; DOI=10.1124/pr.116.012658;
RA   Pirazzini M., Rossetto O., Eleopra R., Montecucco C.;
RT   "Botulinum neurotoxins: Biology, pharmacology, and toxicology.";
RL   Pharmacol. Rev. 69:200-235(2017).
RN   [44] {ECO:0007744|PDB:1XTF, ECO:0007744|PDB:1XTG}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 2-420 IN COMPLEX WITH ZINC WITH
RP   AND WITHOUT SUBSTRATE, FUNCTION (BOTULINUM NEUROTOXIN A LIGHT CHAIN),
RP   SUBSTRATE SPECIFICITY, AND COFACTOR.
RC   STRAIN=Type A;
RX   PubMed=15592454; DOI=10.1038/nature03123;
RA   Breidenbach M.A., Brunger A.T.;
RT   "Substrate recognition strategy for botulinum neurotoxin serotype A.";
RL   Nature 432:925-929(2004).
RN   [45]
RP   STRUCTURE BY ELECTRON MICROSCOPY (24.0 ANGSTROMS), AND DOMAIN.
RC   STRAIN=Type A;
RX   PubMed=18032388; DOI=10.1074/jbc.m707917200;
RA   Fischer A., Garcia-Rodriguez C., Geren I., Lou J., Marks J.D., Nakagawa T.,
RA   Montal M.;
RT   "Molecular architecture of botulinum neurotoxin E revealed by single
RT   particle electron microscopy.";
RL   J. Biol. Chem. 283:3997-4003(2008).
RN   [46] {ECO:0007744|PDB:2VU9, ECO:0007744|PDB:2VUA}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 874-1296 IN COMPLEX WITH
RP   GANGLIOSIDE GT1B ANALOG, FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND
RP   GANGLIOSIDE-BINDING.
RC   STRAIN=Type A;
RX   PubMed=18704164; DOI=10.1371/journal.ppat.1000129;
RA   Stenmark P., Dupuy J., Imamura A., Kiso M., Stevens R.C.;
RT   "Crystal structure of botulinum neurotoxin type A in complex with the cell
RT   surface co-receptor GT1b-insight into the toxin-neuron interaction.";
RL   PLoS Pathog. 4:e1000129-e1000129(2008).
RN   [47] {ECO:0007744|PDB:2W2D}
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 1-445 AND 447-877 IN COMPLEX WITH
RP   ZINC, FUNCTION (BOTULINUM NEUROTOXIN A LIGHT AND HEAVY CHAIN), COFACTOR,
RP   DOMAIN, AND DISULFIDE BONDS.
RC   STRAIN=NCTC 2916 / Type A;
RX   PubMed=19351593; DOI=10.1016/j.bbrc.2009.02.003;
RA   Masuyer G., Thiyagarajan N., James P.L., Marks P.M., Chaddock J.A.,
RA   Acharya K.R.;
RT   "Crystal structure of a catalytically active, non-toxic endopeptidase
RT   derivative of Clostridium botulinum toxin A.";
RL   Biochem. Biophys. Res. Commun. 381:50-53(2009).
RN   [48] {ECO:0007744|PDB:3V0A, ECO:0007744|PDB:3V0B, ECO:0007744|PDB:3V0C}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) IN COMPLEX WITH ZINC AND NTNHA,
RP   FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), COFACTOR, SUBUNIT, DOMAIN,
RP   DISULFIDE BONDS, AND MUTAGENESIS OF 861-ARG--LYS-871; 862-LEU--THR-867;
RP   GLU-982; LYS-1000; ASP-1037; ASP-1118 AND ASP-1171.
RC   STRAIN=Type A;
RX   PubMed=22363010; DOI=10.1126/science.1214270;
RA   Gu S., Rumpel S., Zhou J., Strotmeier J., Bigalke H., Perry K.,
RA   Shoemaker C.B., Rummel A., Jin R.;
RT   "Botulinum neurotoxin is shielded by NTNHA in an interlocked complex.";
RL   Science 335:977-981(2012).
RN   [49] {ECO:0007744|PDB:4JRA}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 871-1296 IN COMPLEX WITH SV2C
RP   RECEPTOR FRAGMENT, FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), SUBUNIT,
RP   SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND MUTAGENESIS
RP   OF 1145-THR-THR-1146; ARG-1156 AND ARG-1294.
RC   STRAIN=Type A;
RX   PubMed=24240280; DOI=10.1038/nature12732;
RA   Benoit R.M., Frey D., Hilbert M., Kevenaar J.T., Wieser M.M.,
RA   Stirnimann C.U., McMillan D., Ceska T., Lebon F., Jaussi R.,
RA   Steinmetz M.O., Schertler G.F., Hoogenraad C.C., Capitani G.,
RA   Kammerer R.A.;
RT   "Structural basis for recognition of synaptic vesicle protein 2C by
RT   botulinum neurotoxin A.";
RL   Nature 505:108-111(2014).
RN   [50] {ECO:0007744|PDB:5JLV, ECO:0007744|PDB:5JMC}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 872-1296 IN COMPLEX WITH HUMAN
RP   AND SV2C RECEPTOR, FUNCTION (BOTULINUM NEUROTOXIN TYPE A AND BOTULINUM
RP   NEUROTOXIN A HEAVY CHAIN), SV2 GLYCAN-BINDING, AND MUTAGENESIS OF PHE-953;
RP   HIS-1064; 1145-THR-THR-1146; ARG-1156; GLY-1292 AND ARG-1294.
RC   STRAIN=Type A;
RX   PubMed=27294781; DOI=10.1038/nsmb.3245;
RA   Yao G., Zhang S., Mahrhold S., Lam K.H., Stern D., Bagramyan K., Perry K.,
RA   Kalkum M., Rummel A., Dong M., Jin R.;
RT   "N-linked glycosylation of SV2 is required for binding and uptake of
RT   botulinum neurotoxin A.";
RL   Nat. Struct. Mol. Biol. 23:656-662(2016).
RN   [51] {ECO:0007744|PDB:5TPB, ECO:0007744|PDB:5TPC}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 876-1296 IN COMPLEX WITH
RP   GANGLIOSIDE ANALOG, AND FUNCTION (BOTULINUM NEUROTOXIN A HEAVY CHAIN).
RC   STRAIN=Type A;
RX   PubMed=27958736; DOI=10.1021/jacs.6b09534;
RA   Hamark C., Berntsson R.P., Masuyer G., Henriksson L.M., Gustafsson R.,
RA   Stenmark P., Widmalm G.;
RT   "Glycans confer specificity to the recognition of ganglioside receptors by
RT   botulinum neurotoxin A.";
RL   J. Am. Chem. Soc. 139:218-230(2017).
RN   [52] {ECO:0007744|PDB:5MK6, ECO:0007744|PDB:5MK7}
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 871-1296, AND DISULFIDE BOND.
RX   PubMed=29576992; DOI=10.7717/peerj.4552;
RA   Davies J.R., Hackett G.S., Liu S.M., Acharya K.R.;
RT   "High resolution crystal structures of the receptor-binding domain of
RT   Clostridium botulinum neurotoxin serotypes A and FA.";
RL   PeerJ 6:E4552-E4552(2018).
CC   -!- FUNCTION: [Botulinum neurotoxin type A]: Botulinum toxin causes flaccid
CC       paralysis by inhibiting neurotransmitter (acetylcholine) release from
CC       the presynaptic membranes of nerve terminals of the eukaryotic host
CC       skeletal and autonomic nervous system, with frequent heart or
CC       respiratory failure (PubMed:15394302, PubMed:7578132). Precursor of
CC       botulinum neurotoxin A which has 2 coreceptors; complex polysialylated
CC       gangliosides found on neural tissue and specific membrane-anchored
CC       proteins of synaptic vesicles. Receptor proteins are exposed on host
CC       presynaptic cell membrane during neurotransmitter release, when the
CC       toxin heavy chain (HC) binds to them. Upon synaptic vesicle recycling
CC       the toxin is taken up via the endocytic pathway. When the pH of the
CC       toxin-containing endosome drops a structural rearrangement occurs so
CC       that the N-terminus of the HC forms pores that allows the light chain
CC       (LC) to translocate into the cytosol (PubMed:17666397,
CC       PubMed:19096517). Once in the cytosol the disulfide bond linking the 2
CC       subunits is reduced and LC cleaves its target protein on synaptic
CC       vesicles, preventing their fusion with the cytoplasmic membrane and
CC       thus neurotransmitter release. Toxin activity requires polysialylated
CC       gangliosides; GT1b supports activity better than GD1a
CC       (PubMed:12089155). Binds to host peripheral neuronal presynaptic
CC       membranes via the synaptic vesicle glycoproteins SV2A, SV2B and SV2C
CC       (PubMed:16543415). It binds directly to the largest lumenal
CC       (intravesicular) loop of SV2A, SV2B and SV2C that is transiently
CC       exposed outside of cells during exocytosis; gangliosides enhance
CC       binding (PubMed:16543415, PubMed:16545378, PubMed:18815274). Recognizes
CC       an N-linked glycan on SV2 proteins (PubMed:18815274, PubMed:27294781).
CC       May also use FGFR3 as a receptor (PubMed:23696738). Toxin uptake into
CC       neural cells requires stimulation (incubation with K(+) to stimulate
CC       receptor exposure) to be internalized by receptor-mediated endocytosis
CC       (PubMed:16543415, PubMed:19650874, PubMed:21632541, PubMed:21832053).
CC       Subsequently the toxin colocalizes with its receptor in host cells
CC       (PubMed:16543415, PubMed:19650874). Toxin uptake can be blocked by the
CC       appropriate SV2 protein fragments in cell culture (PubMed:16543415).
CC       {ECO:0000269|PubMed:12089155, ECO:0000269|PubMed:15394302,
CC       ECO:0000269|PubMed:16543415, ECO:0000269|PubMed:16545378,
CC       ECO:0000269|PubMed:17666397, ECO:0000269|PubMed:18815274,
CC       ECO:0000269|PubMed:19096517, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:21632541, ECO:0000269|PubMed:21832053,
CC       ECO:0000269|PubMed:23696738, ECO:0000269|PubMed:27294781,
CC       ECO:0000269|PubMed:7578132}.
CC   -!- FUNCTION: [Botulinum neurotoxin A light chain]: Has proteolytic
CC       activity (PubMed:7578132). After translocation into the eukaryotic host
CC       cytosol LC hydrolyzes the '197-Gln-|-Arg-198' bond in SNAP25, blocking
CC       neurotransmitter release (PubMed:8243676, PubMed:7578132,
CC       PubMed:9886085, PubMed:10694409, PubMed:11700044, PubMed:11827515,
CC       PubMed:19351593). Recognizes the '146-Met--Gly-155' region of SNAP25,
CC       which confers substrate specificity (PubMed:9886085, PubMed:15592454).
CC       Hydrolyzes the '202-Thr-|-Arg-203' bond of mouse SNAP23, but not in
CC       human which has a different sequence (PubMed:9886085). Reduction of the
CC       interchain disulfide bond occurs in the host cytosol and probably
CC       prevents retrotranslocation into the synaptic vesicle
CC       (PubMed:17666397). Has slow (occurs over 4 weeks) autocatalytic
CC       cleavage, however it is not clear if this is physiologically relevant
CC       (PubMed:11565902). {ECO:0000269|PubMed:10694409,
CC       ECO:0000269|PubMed:11565902, ECO:0000269|PubMed:11700044,
CC       ECO:0000269|PubMed:11827515, ECO:0000269|PubMed:15592454,
CC       ECO:0000269|PubMed:17666397, ECO:0000269|PubMed:7578132,
CC       ECO:0000269|PubMed:8243676, ECO:0000269|PubMed:9886085,
CC       ECO:0000305|PubMed:19351593}.
CC   -!- FUNCTION: [Botulinum neurotoxin A heavy chain]: Responsible for host
CC       epithelial cell transcytosis, host nerve cell targeting and
CC       translocation of botulinum neurotoxin A light chain (LC) into host
CC       cytosol. Composed of 3 subdomains; the translocation domain (TD), and
CC       N-terminus and C-terminus of the receptor-binding domain (RBD)
CC       (PubMed:19096517). The RBD is responsible for binding to host
CC       epithelial cells and transcytosis across them; this uses different
CC       receptors than those on nerve cells (PubMed:21106906). RBD is also
CC       responsible for adherence of toxin to host nerve cell surface; HC alone
CC       prevents uptake of whole toxin by neural cells, and delays paralysis
CC       onset by 75% (PubMed:6694738, PubMed:10413679). Isolated RBD also
CC       delays paralysis onset (PubMed:21106906). The N-terminus of the RBD
CC       binds to phosphatidylinositol, which might play a role in membrane-
CC       binding (PubMed:19161982). Binds to host protein receptor synaptic
CC       vesicle glycoproteins SV2A, SV2B and SV2C via lumenal loop 4
CC       (PubMed:16545378, PubMed:6370252, PubMed:27294781, PubMed:24240280,
CC       PubMed:19650874, PubMed:27313224). Binding can be inhibited by protein
CC       fragments from either the HC or SV2C (PubMed:24240280). Isolated HC
CC       significantly decreases uptake and toxicity of whole BoNT/A, but also
CC       interferes with uptake of BoNT/E and to a lesser extent BoNT/F
CC       (PubMed:19650874). The RBD recognizes the N-linked glycan on 'Asn-559'
CC       of SV2A, SV2B and SV2C; hydrogen-bonding occurs via 10 well-defined
CC       water molecules and stacking of hydrophobic residues (PubMed:27294781).
CC       Binds one host GT1b ganglioside, which serves as a coreceptor
CC       (PubMed:14731268, PubMed:18704164, PubMed:27958736). Modeling shows the
CC       HC can bind both coreceptors (a ganglioside and SV2 protein)
CC       simultaneously at different sites (PubMed:24240280). Crystals of the
CC       RBD with a GT1b analog can be grown at pH 5.5, indicating the toxin-
CC       ganglioside complex could be stable within the endosome
CC       (PubMed:18704164). Isolated RBD binds NTNHA (a bacterial protein that
CC       protects toxin) with high affinity at pH 6.0 but not at pH 7.5
CC       (PubMed:22363010). The N-terminal belt (residues 449-545) wraps around
CC       the perimeter of the LC, probably protecting Zn(2+) in the active site;
CC       it is not required for channel formation by the TD domain but may serve
CC       to prevent premature LC dissociation from the translocation channel and
CC       to protect toxin prior to translocation (PubMed:22158863,
CC       PubMed:17907800, PubMed:19351593). The isolated TD forms transmembrane
CC       channels of about 15 Angstroms in the absence of a pH gradient; LC
CC       translocation requires a pH and redox gradient (pH 5.0/oxidizing in the
CC       cis compartment, pH 7.0/reducing in the trans compartment), LC does not
CC       unfold unless the cis pH is 6.0 or less (PubMed:2446925,
CC       PubMed:17666397, PubMed:19096517). Pores are presumably made by 1-2
CC       toxin molecules (PubMed:23471747). While interaction with the RBD
CC       modulates the pH threshold for membrane insertion, the RBD is not
CC       essential for toxin degradation of SNAP25 in neural cells
CC       (PubMed:19096517). {ECO:0000269|PubMed:10413679,
CC       ECO:0000269|PubMed:14731268, ECO:0000269|PubMed:16545378,
CC       ECO:0000269|PubMed:17666397, ECO:0000269|PubMed:18704164,
CC       ECO:0000269|PubMed:19096517, ECO:0000269|PubMed:19161982,
CC       ECO:0000269|PubMed:19351593, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:21106906, ECO:0000269|PubMed:22158863,
CC       ECO:0000269|PubMed:22363010, ECO:0000269|PubMed:23471747,
CC       ECO:0000269|PubMed:24240280, ECO:0000269|PubMed:27294781,
CC       ECO:0000269|PubMed:27313224, ECO:0000269|PubMed:27958736,
CC       ECO:0000269|PubMed:6694738, ECO:0000305|PubMed:17907800,
CC       ECO:0000305|PubMed:2446925}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Limited hydrolysis of proteins of the neuroexocytosis
CC         apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on
CC         small molecule substrates.; EC=3.4.24.69;
CC         Evidence={ECO:0000269|PubMed:10694409, ECO:0000269|PubMed:7578132,
CC         ECO:0000269|PubMed:8243676, ECO:0000269|PubMed:9886085};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11565902, ECO:0000269|PubMed:11700044,
CC         ECO:0000269|PubMed:1429690, ECO:0000269|PubMed:15592454,
CC         ECO:0000269|PubMed:19351593, ECO:0000269|PubMed:22363010,
CC         ECO:0000269|PubMed:7578132};
CC       Note=Binds 1 zinc ion per subunit (PubMed:1429690, PubMed:11700044,
CC       PubMed:15592454, PubMed:19351593, PubMed:22363010).
CC       {ECO:0000269|PubMed:11700044, ECO:0000269|PubMed:1429690,
CC       ECO:0000269|PubMed:15592454, ECO:0000269|PubMed:19351593,
CC       ECO:0000269|PubMed:22363010};
CC   -!- ACTIVITY REGULATION: Toxin internalization is inhibited by azide or
CC       dinitrophenol or at 4 degrees Celsius (PubMed:6694738). Dynamin (DNM)
CC       inhibitors abolish toxin uptake (PubMed:21832053).
CC       {ECO:0000269|PubMed:21832053, ECO:0000269|PubMed:6694738}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=41 uM for purified SNAP25 with isolated botulinum neurotoxin A
CC         light chain {ECO:0000269|PubMed:10694409};
CC         KM=9.8 uM for purified SNAP25 with isolated botulinum neurotoxin A
CC         light chain {ECO:0000269|PubMed:11827515};
CC         Note=kcat is 140 min(-1) (PubMed:10694409). kcat is 1026 (-1)
CC         (PubMed:11827515). {ECO:0000269|PubMed:10694409,
CC         ECO:0000269|PubMed:11827515};
CC   -!- SUBUNIT: Heterodimer; disulfide-linked heterodimer of a light chain
CC       (LC) and heavy chain (HC) (PubMed:7578132). Interacts with glycosylated
CC       host synaptic vesicle glycoproteins SV2A, SV2B and SV2C which serve as
CC       coreceptors (PubMed:16543415, PubMed:18815274, PubMed:19650874,
CC       PubMed:24240280, PubMed:27313224). Glycosylation of 'Asn-559' in SV2C
CC       contributes a 12-fold increase in affinity to this interaction
CC       (PubMed:27313224). Depolarization of target tissue with high levels of
CC       K(+) leads to greater levels of receptor exposure (PubMed:16543415). In
CC       vitro addition of gangliosides increases SV2-toxin interaction
CC       (PubMed:16543415). Forms a highly interlocked heterodimer with NTNHA at
CC       pH 6.0 but not at pH 7.5 called the minimally functional progenitor
CC       toxin complex (M-PTC) (PubMed:22363010). The PTC is thought to protect
CC       toxin in the host acidic gastrointestinal tract, facilitate
CC       transcytosis across the intestinal barrier and release at neutral pH as
CC       is found in the bloodstream (PubMed:22363010).
CC       {ECO:0000269|PubMed:16543415, ECO:0000269|PubMed:16545378,
CC       ECO:0000269|PubMed:18815274, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:22363010, ECO:0000269|PubMed:24240280,
CC       ECO:0000269|PubMed:27313224, ECO:0000269|PubMed:7578132,
CC       ECO:0000305|PubMed:22363010}.
CC   -!- INTERACTION:
CC       P0DPI0; Q02563: Sv2a; Xeno; NbExp=2; IntAct=EBI-8178893, EBI-466194;
CC       P0DPI0; Q496J9: SV2C; Xeno; NbExp=4; IntAct=EBI-8178893, EBI-16081469;
CC       P0DPI0; Q9Z2I6: Sv2c; Xeno; NbExp=12; IntAct=EBI-8178893, EBI-8178859;
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin type A]: Secreted
CC       {ECO:0000269|PubMed:7592120}. Secreted, cell wall
CC       {ECO:0000269|PubMed:7592120}. Host synapse, host presynaptic cell
CC       membrane {ECO:0000269|PubMed:6694738}. Note=Whole toxin may be released
CC       from the bacteria during cell wall exfoliation (PubMed:7592120). There
CC       are estimated to be 150-500 toxin molecules per um(2) of non-myelinated
CC       mouse hemidiaphragm nerve membrane (PubMed:6694738). In mouse
CC       hemidiaphragm binds only to nerve terminals, and not to muscle, blood
CC       vessels, connective tissue Schwann cells or myelin, toxin can be
CC       internalized by this preparation (PubMed:6694738).
CC       {ECO:0000269|PubMed:6694738, ECO:0000269|PubMed:7592120}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin A light chain]: Secreted
CC       {ECO:0000269|PubMed:6370252}. Host cytoplasm, host cytosol
CC       {ECO:0000305|PubMed:7578132, ECO:0000305|PubMed:8243676,
CC       ECO:0000305|PubMed:9886085}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin A heavy chain]: Secreted
CC       {ECO:0000269|PubMed:6370252}. Host synapse, host presynaptic cell
CC       membrane {ECO:0000269|PubMed:6694738, ECO:0000305|PubMed:10413679}.
CC       Host cytoplasmic vesicle, host secretory vesicle, host synaptic vesicle
CC       membrane {ECO:0000269|PubMed:23471747, ECO:0000305|PubMed:10413679,
CC       ECO:0000305|PubMed:21632541, ECO:0000305|PubMed:21832053,
CC       ECO:0000305|PubMed:24240280, ECO:0000305|PubMed:6694738}; Multi-pass
CC       membrane protein {ECO:0000305|PubMed:17666397,
CC       ECO:0000305|PubMed:19096517, ECO:0000305|PubMed:2446925}. Note=Whole
CC       toxin may be released from the bacteria during cell wall exfoliation
CC       (PubMed:7592120). Colocalizes with its receptor SV2C (synaptic vesicle
CC       glycoprotein 2C) and VGAT (vesicular inhibitory amino acid transporter)
CC       in neurons (PubMed:24240280). In neurons HC colocalizes with
CC       synaptophysin or VAMP2 probably in synaptic vesicles, a portion also
CC       colocalizes with RAB5 and may be in synaptic vesicle protein sorting
CC       endosomes (PubMed:21632541, PubMed:21832053). Therefore there may be
CC       more than one uptake pathway at nerve terminals. Uptake of HC and whole
CC       toxin is slowed by dynamin inhibitors (PubMed:21832053). 1-2 molecules
CC       of HC are found in the host synaptic vesicle lumen, uptake and
CC       subsequent release of LC is very rapid (PubMed:21832053,
CC       PubMed:23471747). {ECO:0000269|PubMed:21632541,
CC       ECO:0000269|PubMed:21832053, ECO:0000269|PubMed:23471747,
CC       ECO:0000269|PubMed:24240280}.
CC   -!- INDUCTION: In cultured bacteria, first detected in late exponential
CC       growth (17 hours), reaches maximal levels at 24-25 hours and remains
CC       nearly constant for 5 days (at protein level).
CC       {ECO:0000269|PubMed:7592120}.
CC   -!- DOMAIN: [Botulinum neurotoxin A light chain]: Has protease activity
CC       (PubMed:7578132). {ECO:0000269|PubMed:7578132}.
CC   -!- DOMAIN: [Botulinum neurotoxin A heavy chain]: Has 3 functional domains;
CC       the translocation domain (TD) and the receptor-binding domain (RBD)
CC       which is further subdivided into N- and C-terminal domains (N-RBD and
CC       C-RBD). Upon trypsin digestion the isolated TD forms channels in
CC       bilayers when the cis side is acidic/oxidizing and the trans side is pH
CC       7.0/reducing (PubMed:2446925, PubMed:17666397, PubMed:19096517). The
CC       RBD rotates 140 degrees around the TD in the presence of NTNHA
CC       (PubMed:22363010). The 3 major domains each serve as a chaperone for
CC       the other 2 to ensure they act only in the correct host cell context
CC       (PubMed:19096517). In BoNT/A structures the LC is separated from the
CC       RBD by the TD; the belt wraps around the perimeter of the LC,
CC       protecting Zn(2+) in the active site (PubMed:18032388, PubMed:19351593,
CC       PubMed:22363010). The belt region (449-545) may be a pseudosubstrate
CC       inhibitor which serves as an intramolecular chaperone for the LC prior
CC       to its translocation into the host cytosol (PubMed:17907800).
CC       {ECO:0000269|PubMed:17666397, ECO:0000269|PubMed:18032388,
CC       ECO:0000269|PubMed:19096517, ECO:0000269|PubMed:19351593,
CC       ECO:0000269|PubMed:22363010, ECO:0000269|PubMed:2446925,
CC       ECO:0000305|PubMed:17907800}.
CC   -!- PTM: In a bacterial culture the precursor chain is initally cleaved on
CC       the amino side of Gly-445 and is processed more slowly between Lys-448
CC       and Ala-449 to give the final mature heavy chain sequence.
CC       {ECO:0000269|PubMed:2126206}.
CC   -!- PTM: [Botulinum neurotoxin A light chain]: Has slow autocatalytic
CC       activity, cleaves 250-Tyr-Tyr-251, 266-Phe-Gly-267, 419-Phe-Thr-420,
CC       423-Phe-Glu-424, 430-Cys-Val-431, 432-Arg-Gly-433, 438-Lys-Thr-439, and
CC       probably 429-Leu-Cys-430 over a period of 4 weeks. Catalysis of the
CC       '197-Gln-|-Arg-198' bond in SNAP25 is estimated to be 10(5) more
CC       efficient than autocatalysis, leaving the physiological importance of
CC       autocatalysis in doubt (PubMed:11565902).
CC       {ECO:0000269|PubMed:11565902}.
CC   -!- PTM: [Botulinum neurotoxin A light chain]: Ubiquitinated by host HECD2.
CC       Deubiquitination by host VCPIP1 prevents degradation by the proteasome.
CC       {ECO:0000269|PubMed:28584101}.
CC   -!- BIOTECHNOLOGY: Dynamin inhibitors slow toxin uptake by nerve cells, and
CC       might be used to prolong the treatment window for antitoxins.
CC       {ECO:0000305|PubMed:21832053}.
CC   -!- BIOTECHNOLOGY: Replacement of the RBD by other proteins (such as wheat
CC       germ agglutinin) allows the rest of the toxin to be taken up by other
CC       cell types, and can be used for investigating synaptic vesicle docking-
CC       dependent processes in BoNT resistant cells (PubMed:10768948). LC
CC       retains protease activity (PubMed:10768948, PubMed:19351593).
CC       {ECO:0000269|PubMed:10768948, ECO:0000269|PubMed:19351593}.
CC   -!- BIOTECHNOLOGY: Isolated receptor-binding domain (RBD) can be used as a
CC       vaccine; a mutated form that is transcytosed into the general
CC       circulation but does not enter nerve cells (Leu-1266-1267-Ser) is as
CC       efficient as wild-type RBD (PubMed:21106906).
CC       {ECO:0000269|PubMed:21106906}.
CC   -!- PHARMACEUTICAL: Available under the name Botox (onabotulinumtoxinA,
CC       Allergan), Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) and
CC       Xeomin (incobotulinumtoxinA, Merz Pharmaceuticals) for the treatment of
CC       strabismus and blepharospasm associated with dystonia and cervical
CC       dystonia. Also used for the treatment of hemifacial spasm and a number
CC       of other neurological disorders characterized by abnormal muscle
CC       contraction. It is also used cosmetically to smooth facial wrinkles.
CC       {ECO:0000305|PubMed:28356439}.
CC   -!- MISCELLANEOUS: There are seven antigenically distinct forms of
CC       botulinum neurotoxin: Types A, B, C, D, E, F, and G; new subtypes are
CC       quite frequent. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Types A, B and E are the most frequent cause of adult
CC       human foodborne botulism; type A is the most severe, while type E has
CC       the shortest incubation period (PubMed:1431246).
CC       {ECO:0000269|PubMed:1431246}.
CC   -!- MISCELLANEOUS: Neurotoxin type A is released from bacteria in the two-
CC       chain form (PubMed:6370252, PubMed:2126206).
CC       {ECO:0000269|PubMed:2126206, ECO:0000269|PubMed:6370252}.
CC   -!- MISCELLANEOUS: Botulism poisoning is usually food-borne, either by
CC       ingesting toxin or bacterial-contaminated food, or less frequently by
CC       inhalation poisoning. In both cases the neurotoxin binds to the apical
CC       surface of epithelial cells in the gut or airway. Toxin undergoes
CC       receptor-mediated endocytosis (using a different receptor than on
CC       target nerve cells), transcytosis across the epithelial cells and
CC       release into the general circulation. Once in the general circulation
CC       it binds to its target cells. {ECO:0000305|PubMed:21106906}.
CC   -!- SIMILARITY: Belongs to the peptidase M27 family. {ECO:0000305}.
CC   -!- CAUTION: Contradictory results show that only SV2C is the receptor; in
CC       these experiments gangliosides do not improve toxin-coreceptor
CC       interaction (PubMed:16545378). {ECO:0000269|PubMed:16545378}.
CC   -!- WEB RESOURCE: Name=BOTOX product information Web site;
CC       URL="https://www.botox.com/";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=From sausages to wrinkles
CC       - Issue 19 of February 2002;
CC       URL="https://web.expasy.org/spotlight/back_issues/019";
CC   -!- WEB RESOURCE: Name=BotDB - A Database Resource for Clostridial
CC       Neurotoxins;
CC       URL="https://botdb.abcc.ncifcrf.gov/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52066; CAA36289.1; -; Genomic_DNA.
DR   EMBL; M30196; AAA23262.1; -; Genomic_DNA.
DR   EMBL; X92973; CAA63551.1; -; Genomic_DNA.
DR   EMBL; D67030; BAA11051.1; -; Genomic_DNA.
DR   PIR; A35294; BTCLAB.
DR   RefSeq; WP_003356619.1; NZ_LFOS01000037.1.
DR   RefSeq; WP_011948511.1; NZ_LHUL01000004.1.
DR   PDB; 1XTF; X-ray; 2.20 A; A/B=2-420.
DR   PDB; 1XTG; X-ray; 2.10 A; A=2-420.
DR   PDB; 2ILP; X-ray; 1.90 A; A/B=3-424.
DR   PDB; 2IMA; X-ray; 1.94 A; A/B=1-424.
DR   PDB; 2IMB; X-ray; 2.41 A; A/B=3-424.
DR   PDB; 2IMC; X-ray; 2.00 A; A/B=3-424.
DR   PDB; 2ISE; X-ray; 2.20 A; A/B=1-420.
DR   PDB; 2ISG; X-ray; 2.00 A; A/B=1-420.
DR   PDB; 2ISH; X-ray; 2.00 A; A/B=1-420.
DR   PDB; 2VU9; X-ray; 1.60 A; A=876-1296.
DR   PDB; 2VUA; X-ray; 1.70 A; A=876-1296.
DR   PDB; 2W2D; X-ray; 2.59 A; A/C=3-442, B/D=447-877.
DR   PDB; 3BOK; X-ray; 1.25 A; A=3-425.
DR   PDB; 3BON; X-ray; 1.20 A; A=3-425.
DR   PDB; 3BOO; X-ray; 1.40 A; A=3-425.
DR   PDB; 3V0A; X-ray; 2.70 A; A=1-1296.
DR   PDB; 3V0B; X-ray; 3.90 A; A=1-1296.
DR   PDB; 3V0C; X-ray; 4.30 A; A=1-1296.
DR   PDB; 3ZUR; X-ray; 2.71 A; A/B=3-430, A/B=454-865.
DR   PDB; 3ZUS; X-ray; 2.95 A; A/B/C/D=3-431, A/B/C/D=454-865.
DR   PDB; 4HEV; X-ray; 2.50 A; A/B=1-425.
DR   PDB; 4IQP; X-ray; 2.30 A; A=871-1296.
DR   PDB; 4JRA; X-ray; 2.30 A; A/B=871-1296.
DR   PDB; 5JLV; X-ray; 2.00 A; A/B=872-1296.
DR   PDB; 5JMC; X-ray; 2.64 A; A/C/E/G=872-1296.
DR   PDB; 5MK6; X-ray; 1.45 A; A=871-1296.
DR   PDB; 5MK7; X-ray; 1.80 A; A=871-1296.
DR   PDB; 5TPB; X-ray; 2.60 A; A/B=876-1296.
DR   PDB; 5TPC; X-ray; 2.00 A; A=876-1296.
DR   PDB; 5V8P; X-ray; 2.50 A; A/B=1-424.
DR   PDB; 5V8R; X-ray; 1.90 A; A/B=1-424.
DR   PDB; 5V8U; X-ray; 2.05 A; A/B=1-424.
DR   PDB; 5VGV; X-ray; 2.60 A; A=1-425.
DR   PDB; 5VGX; X-ray; 2.15 A; A=1-425.
DR   PDB; 6DKK; X-ray; 2.70 A; A/B=547-871.
DR   PDB; 6MHJ; X-ray; 3.02 A; A=547-871.
DR   PDB; 6XCB; X-ray; 1.74 A; A=3-424.
DR   PDB; 6XCC; X-ray; 1.90 A; A=3-424.
DR   PDB; 6XCD; X-ray; 1.92 A; A=3-424.
DR   PDB; 6XCE; X-ray; 2.50 A; A=3-424.
DR   PDB; 6XCF; X-ray; 1.68 A; A=3-424.
DR   PDB; 7KYF; X-ray; 2.33 A; C=1-417.
DR   PDB; 7KYH; X-ray; 2.91 A; A/B/C/D=1-417.
DR   PDB; 7LZP; X-ray; 2.86 A; A/D=2-438.
DR   PDB; 7M1H; X-ray; 2.78 A; A=2-438.
DR   PDBsum; 1XTF; -.
DR   PDBsum; 1XTG; -.
DR   PDBsum; 2ILP; -.
DR   PDBsum; 2IMA; -.
DR   PDBsum; 2IMB; -.
DR   PDBsum; 2IMC; -.
DR   PDBsum; 2ISE; -.
DR   PDBsum; 2ISG; -.
DR   PDBsum; 2ISH; -.
DR   PDBsum; 2VU9; -.
DR   PDBsum; 2VUA; -.
DR   PDBsum; 2W2D; -.
DR   PDBsum; 3BOK; -.
DR   PDBsum; 3BON; -.
DR   PDBsum; 3BOO; -.
DR   PDBsum; 3V0A; -.
DR   PDBsum; 3V0B; -.
DR   PDBsum; 3V0C; -.
DR   PDBsum; 3ZUR; -.
DR   PDBsum; 3ZUS; -.
DR   PDBsum; 4HEV; -.
DR   PDBsum; 4IQP; -.
DR   PDBsum; 4JRA; -.
DR   PDBsum; 5JLV; -.
DR   PDBsum; 5JMC; -.
DR   PDBsum; 5MK6; -.
DR   PDBsum; 5MK7; -.
DR   PDBsum; 5TPB; -.
DR   PDBsum; 5TPC; -.
DR   PDBsum; 5V8P; -.
DR   PDBsum; 5V8R; -.
DR   PDBsum; 5V8U; -.
DR   PDBsum; 5VGV; -.
DR   PDBsum; 5VGX; -.
DR   PDBsum; 6DKK; -.
DR   PDBsum; 6MHJ; -.
DR   PDBsum; 6XCB; -.
DR   PDBsum; 6XCC; -.
DR   PDBsum; 6XCD; -.
DR   PDBsum; 6XCE; -.
DR   PDBsum; 6XCF; -.
DR   PDBsum; 7KYF; -.
DR   PDBsum; 7KYH; -.
DR   PDBsum; 7LZP; -.
DR   PDBsum; 7M1H; -.
DR   AlphaFoldDB; P0DPI0; -.
DR   SMR; P0DPI0; -.
DR   IntAct; P0DPI0; 4.
DR   MINT; P0DPI0; -.
DR   BindingDB; P0DPI0; -.
DR   ChEMBL; CHEMBL5192; -.
DR   UniLectin; P0DPI0; -.
DR   ABCD; P0DPI0; 61 sequenced antibodies.
DR   GeneID; 5185061; -.
DR   Reactome; R-HSA-5250968; Toxicity of botulinum toxin type A (botA).
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044161; C:host cell cytoplasmic vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044164; C:host cell cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0044156; C:host cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0044231; C:host cell presynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:1905576; F:ganglioside GT1b binding; IDA:UniProtKB.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008320; F:protein transmembrane transporter activity; EXP:Reactome.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:InterPro.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1120.10; -; 1.
DR   InterPro; IPR000395; Bot/tetX_LC.
DR   InterPro; IPR036248; Clostridium_toxin_transloc.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011065; Kunitz_inhibitor_STI-like_sf.
DR   InterPro; IPR013104; Toxin_rcpt-bd_C.
DR   InterPro; IPR012928; Toxin_rcpt-bd_N.
DR   InterPro; IPR012500; Toxin_trans.
DR   Pfam; PF01742; Peptidase_M27; 1.
DR   Pfam; PF07951; Toxin_R_bind_C; 1.
DR   Pfam; PF07953; Toxin_R_bind_N; 1.
DR   Pfam; PF07952; Toxin_trans; 1.
DR   PRINTS; PR00760; BONTOXILYSIN.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF50386; SSF50386; 1.
DR   SUPFAM; SSF58091; SSF58091; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell wall; Direct protein sequencing; Disulfide bond;
KW   Host cell membrane; Host cytoplasm; Host cytoplasmic vesicle;
KW   Host membrane; Host synapse; Hydrolase; Lipid-binding; Membrane;
KW   Metal-binding; Metalloprotease; Neurotoxin; Pharmaceutical; Protease;
KW   Secreted; Toxin; Transmembrane; Transmembrane helix; Ubl conjugation;
KW   Virulence; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:2126206,
FT                   ECO:0000269|PubMed:6370252, ECO:0000269|Ref.6,
FT                   ECO:0000305|PubMed:11565902"
FT   CHAIN           2..1296
FT                   /note="Botulinum neurotoxin type A"
FT                   /id="PRO_0000444902"
FT   CHAIN           2..448
FT                   /note="Botulinum neurotoxin A light chain"
FT                   /evidence="ECO:0000269|PubMed:6370252"
FT                   /id="PRO_0000029211"
FT   CHAIN           449..1296
FT                   /note="Botulinum neurotoxin A heavy chain"
FT                   /evidence="ECO:0000269|PubMed:6370252"
FT                   /id="PRO_0000029212"
FT   TRANSMEM        627..647
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        656..676
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   REGION          449..870
FT                   /note="Translocation domain (TD); not required to bind
FT                   NTNHA"
FT                   /evidence="ECO:0000269|PubMed:22363010,
FT                   ECO:0000305|PubMed:19096517"
FT   REGION          492..545
FT                   /note="Belt; not required for channel formation"
FT                   /evidence="ECO:0000305|PubMed:22158863"
FT   REGION          871..1092
FT                   /note="N-terminus of receptor binding domain (N-RBD)"
FT                   /evidence="ECO:0000305|PubMed:19096517"
FT   REGION          1093..1296
FT                   /note="C-terminus of receptor binding domain (C-RBD)"
FT                   /evidence="ECO:0000305|PubMed:19096517"
FT   REGION          1252..1253
FT                   /note="Interaction with host ganglioside GT1b"
FT                   /evidence="ECO:0000269|PubMed:18704164,
FT                   ECO:0000269|PubMed:27958736, ECO:0000305|PubMed:14731268,
FT                   ECO:0007744|PDB:2VU9, ECO:0007744|PDB:5TPB,
FT                   ECO:0007744|PDB:5TPC"
FT   MOTIF           1264..1267
FT                   /note="Host ganglioside-binding motif; interacts with GT1b"
FT                   /evidence="ECO:0000269|PubMed:18704164,
FT                   ECO:0000269|PubMed:27958736, ECO:0000305|PubMed:14731268,
FT                   ECO:0000305|PubMed:19650874, ECO:0007744|PDB:2VU9,
FT                   ECO:0007744|PDB:5TPB, ECO:0007744|PDB:5TPC"
FT   ACT_SITE        224
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095,
FT                   ECO:0000305|PubMed:10694409"
FT   BINDING         223
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095,
FT                   ECO:0000269|PubMed:15592454, ECO:0000269|PubMed:19351593,
FT                   ECO:0007744|PDB:1XTF, ECO:0007744|PDB:1XTG,
FT                   ECO:0007744|PDB:2W2D, ECO:0007744|PDB:3V0A,
FT                   ECO:0007744|PDB:3V0B"
FT   BINDING         227
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095,
FT                   ECO:0000269|PubMed:15592454, ECO:0000269|PubMed:19351593,
FT                   ECO:0000305|PubMed:7578132, ECO:0007744|PDB:1XTF,
FT                   ECO:0007744|PDB:1XTG, ECO:0007744|PDB:2W2D,
FT                   ECO:0007744|PDB:3V0A, ECO:0007744|PDB:3V0B"
FT   BINDING         262
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:15592454,
FT                   ECO:0000269|PubMed:19351593, ECO:0000305|PubMed:11700044,
FT                   ECO:0007744|PDB:1XTF, ECO:0007744|PDB:1XTG,
FT                   ECO:0007744|PDB:2W2D, ECO:0007744|PDB:3V0A,
FT                   ECO:0007744|PDB:3V0B"
FT   BINDING         1117
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /ligand_note="host ganglioside"
FT                   /evidence="ECO:0000269|PubMed:18704164,
FT                   ECO:0000269|PubMed:27958736, ECO:0007744|PDB:2VU9,
FT                   ECO:0007744|PDB:5TPB, ECO:0007744|PDB:5TPC"
FT   BINDING         1203
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /ligand_note="host ganglioside"
FT                   /evidence="ECO:0000269|PubMed:18704164,
FT                   ECO:0000269|PubMed:27958736, ECO:0000305|PubMed:14731268,
FT                   ECO:0007744|PDB:2VU9, ECO:0007744|PDB:5TPB,
FT                   ECO:0007744|PDB:5TPC"
FT   SITE            363
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000305|PubMed:11827515"
FT   SITE            366
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000305|PubMed:11827515"
FT   DISULFID        430..454
FT                   /note="Interchain (between light and heavy chains)"
FT                   /evidence="ECO:0000269|PubMed:19351593,
FT                   ECO:0000269|PubMed:22363010, ECO:0000305|PubMed:17666397,
FT                   ECO:0007744|PDB:2W2D, ECO:0007744|PDB:3V0A,
FT                   ECO:0007744|PDB:3V0B, ECO:0007744|PDB:3V0C"
FT   DISULFID        1235..1280
FT                   /evidence="ECO:0007744|PDB:3V0C, ECO:0007744|PDB:5MK7"
FT   VARIANT         27
FT                   /note="V -> A (in strain: 62A)"
FT   MUTAGEN         224
FT                   /note="E->D: Light chain has 5% cleavage activity on
FT                   SNAP25. KM for SNAP25 is nearly wild-type."
FT                   /evidence="ECO:0000269|PubMed:10694409"
FT   MUTAGEN         224
FT                   /note="E->Q: Light chain no longer cleaves SNAP25, no
FT                   effect on substrate or Zn(2+) binding."
FT                   /evidence="ECO:0000269|PubMed:10694409"
FT   MUTAGEN         227
FT                   /note="H->Y: Light chain no longer cleaves SNAP25, not
FT                   toxic in vitro or in vivo when reconstituted with heavy
FT                   chain."
FT                   /evidence="ECO:0000269|PubMed:7578132"
FT   MUTAGEN         262
FT                   /note="E->A: Light chain has 20% cleavage activity on
FT                   SNAP25, 40% decrease in Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:11700044"
FT   MUTAGEN         266
FT                   /note="F->A: Light chain has 50% cleavage activity on
FT                   SNAP25, no effect on Zn(2+) binding."
FT                   /evidence="ECO:0000269|PubMed:11700044"
FT   MUTAGEN         351
FT                   /note="E->A,Q: Wild-type KM for SNAP25, no protease
FT                   activity, about 30% less Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:11827515"
FT   MUTAGEN         363
FT                   /note="R->A,H,K: Wild-type KM for SNAP25, about 75-fold
FT                   decrease in kcat, no effect on Zn(2+) binding."
FT                   /evidence="ECO:0000269|PubMed:11827515"
FT   MUTAGEN         366
FT                   /note="Y->A: Light chain has 40% cleavage activity on
FT                   SNAP25, 30% decrease in Zn(2+)."
FT                   /evidence="ECO:0000269|PubMed:11700044"
FT   MUTAGEN         366
FT                   /note="Y->F: About wild-type KM for SNAP25, 35-fold
FT                   decrease in kcat, no effect on Zn(2+) binding."
FT                   /evidence="ECO:0000269|PubMed:11827515"
FT   MUTAGEN         861..871
FT                   /note="RLLSTFTEYIK->ALLSTFTPYIP: Reduced toxicity."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         862..867
FT                   /note="LLSTFT->KESTFK: Reduced toxicity."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         953
FT                   /note="F->G: Whole toxin has 50-fold reduction in toxicity,
FT                   almost no binding of RBD to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   MUTAGEN         953
FT                   /note="F->R: Whole toxin is non-toxic, almost no binding of
FT                   RBD to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   MUTAGEN         982
FT                   /note="E->A,Q: Decreased binding of NTNHA by
FT                   receptor-binding domain (RBD) at pH 7.5."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         1000
FT                   /note="K->A: Decreased binding of NTNHA by RBD at pH 6.0,
FT                   none at pH 7.5."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         1037
FT                   /note="D->A,N: Decreased binding of NTNHA by RBD at pH
FT                   7.5."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         1064
FT                   /note="H->G,R: Whole toxin has reduced toxicity,
FT                   dramatically reduced binding of RBD to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   MUTAGEN         1118
FT                   /note="D->A: Decreased binding of NTNHA by RBD at pH 7.5."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         1145..1146
FT                   /note="TT->AA: No binding of RBD to neurons. Loss of
FT                   binding to SV2C."
FT                   /evidence="ECO:0000269|PubMed:24240280,
FT                   ECO:0000269|PubMed:27294781"
FT   MUTAGEN         1156
FT                   /note="R->E: Decreased binding of RBD to SV2C, substantial
FT                   binding to neurons."
FT                   /evidence="ECO:0000269|PubMed:24240280,
FT                   ECO:0000269|PubMed:27294781"
FT   MUTAGEN         1171
FT                   /note="D->A: Decreased binding of NTNHA by RBD at pH 7.5."
FT                   /evidence="ECO:0000269|PubMed:22363010"
FT   MUTAGEN         1203
FT                   /note="E->L: Strongly reduced toxicity, heavy chain has
FT                   very strongly reduced binding to synaptosomes, decreased
FT                   binding to gangioside GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1253
FT                   /note="H->A: Strongly reduced toxicity, heavy chain has
FT                   very strongly reduced binding to synaptosomes, decrease in
FT                   ganglioside GT1b binding."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1253
FT                   /note="H->W: Heavy chain has very strongly reduced binding
FT                   to synaptosomes, binds much less GT1b. RBD protects against
FT                   neurotoxin less well than wild-type."
FT                   /evidence="ECO:0000269|PubMed:14731268,
FT                   ECO:0000269|PubMed:21106906"
FT   MUTAGEN         1264
FT                   /note="S->A: Reduced toxicity, heavy chain has strongly
FT                   reduced binding to synaptosomes, heavy chain binds less
FT                   GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1266..1267
FT                   /note="WY->LS: Whole RBD does not protect against
FT                   neurotoxin, no effect on epithelial cell passage; can be
FT                   used as a vaccine."
FT                   /evidence="ECO:0000269|PubMed:21106906"
FT   MUTAGEN         1266
FT                   /note="W->L: Nearly complete loss of toxicity, heavy chain
FT                   has very strongly reduced binding to synaptosomes, binds
FT                   much less GT1b. Heavy chain no longer inhibits whole-toxin
FT                   uptake and toxicity. RBD protects against neurotoxin
FT                   considerably less well than wild-type."
FT                   /evidence="ECO:0000269|PubMed:14731268,
FT                   ECO:0000269|PubMed:19650874, ECO:0000269|PubMed:21106906"
FT   MUTAGEN         1267
FT                   /note="Y->F: Nearly complete loss of toxicity, heavy chain
FT                   has very strongly reduced binding to synaptosomes, binds
FT                   much less GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1267
FT                   /note="Y->S: Nearly complete loss of toxicity, heavy chain
FT                   has very strongly reduced binding to synaptosomes, binds
FT                   much less GT1b. RBD protects against neurotoxin
FT                   considerably less well than wild-type."
FT                   /evidence="ECO:0000269|PubMed:14731268,
FT                   ECO:0000269|PubMed:21106906"
FT   MUTAGEN         1292
FT                   /note="G->Q: Whole toxin has very strongly reduced
FT                   toxicity, almost no binding of RBD to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   MUTAGEN         1292
FT                   /note="G->R: Nearly complete loss of toxicity, almost no
FT                   binding of RBD to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   MUTAGEN         1294
FT                   /note="R->A: Decreased binding of RBD to SV2C, substantial
FT                   binding to neurons."
FT                   /evidence="ECO:0000269|PubMed:24240280"
FT   MUTAGEN         1294
FT                   /note="R->S: Decreased binding of RBD to SV2C, substantial
FT                   binding to neurons."
FT                   /evidence="ECO:0000269|PubMed:27294781"
FT   CONFLICT        2
FT                   /note="P -> Q (in Ref. 1; CAA36289)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        480
FT                   /note="E -> P (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          10..12
FT                   /evidence="ECO:0007829|PDB:7KYH"
FT   STRAND          16..23
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            25..27
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          33..39
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          42..48
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          51..53
FT                   /evidence="ECO:0007829|PDB:7KYF"
FT   HELIX           54..56
FT                   /evidence="ECO:0007829|PDB:7LZP"
FT   HELIX           64..66
FT                   /evidence="ECO:0007829|PDB:6XCB"
FT   TURN            68..70
FT                   /evidence="ECO:0007829|PDB:7KYF"
FT   TURN            75..78
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           81..99
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           102..113
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           131..133
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          134..138
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          144..148
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          150..155
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          157..161
FT                   /evidence="ECO:0007829|PDB:7KYH"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            175..177
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          184..187
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          192..196
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           200..203
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          206..208
FT                   /evidence="ECO:0007829|PDB:7M1H"
FT   HELIX           217..232
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           249..253
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           260..266
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           268..273
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           276..299
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          302..308
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           310..321
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:7LZP"
FT   STRAND          327..329
FT                   /evidence="ECO:0007829|PDB:6XCD"
FT   STRAND          331..333
FT                   /evidence="ECO:0007829|PDB:7LZP"
FT   HELIX           335..346
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           351..358
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          366..368
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          372..375
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            381..383
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            386..388
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          393..395
FT                   /evidence="ECO:0007829|PDB:6XCE"
FT   HELIX           396..398
FT                   /evidence="ECO:0007829|PDB:7KYF"
FT   TURN            399..401
FT                   /evidence="ECO:0007829|PDB:7KYH"
FT   HELIX           402..404
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            406..409
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   HELIX           410..412
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   STRAND          414..418
FT                   /evidence="ECO:0007829|PDB:6XCF"
FT   TURN            420..422
FT                   /evidence="ECO:0007829|PDB:6XCE"
FT   STRAND          428..431
FT                   /evidence="ECO:0007829|PDB:7LZP"
FT   STRAND          548..550
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           551..555
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          562..564
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          567..570
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           572..576
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          581..583
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           588..594
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   TURN            600..602
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           603..619
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          622..625
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          627..633
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          636..639
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           643..645
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          646..649
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          653..657
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   STRAND          662..668
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           679..685
FT                   /evidence="ECO:0007829|PDB:6MHJ"
FT   HELIX           688..719
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           721..751
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           756..760
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           766..798
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           800..824
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   TURN            827..832
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           834..845
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           853..856
FT                   /evidence="ECO:0007829|PDB:6DKK"
FT   HELIX           861..868
FT                   /evidence="ECO:0007829|PDB:6DKK"
SQ   SEQUENCE   1296 AA;  149454 MW;  B731EF5BA5E62FDA CRC64;
     MPFVNKQFNY KDPVNGVDIA YIKIPNVGQM QPVKAFKIHN KIWVIPERDT FTNPEEGDLN
     PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VTKLFERIYS TDLGRMLLTS IVRGIPFWGG
     STIDTELKVI DTNCINVIQP DGSYRSEELN LVIIGPSADI IQFECKSFGH EVLNLTRNGY
     GSTQYIRFSP DFTFGFEESL EVDTNPLLGA GKFATDPAVT LAHELIHAGH RLYGIAINPN
     RVFKVNTNAY YEMSGLEVSF EELRTFGGHD AKFIDSLQEN EFRLYYYNKF KDIASTLNKA
     KSIVGTTASL QYMKNVFKEK YLLSEDTSGK FSVDKLKFDK LYKMLTEIYT EDNFVKFFKV
     LNRKTYLNFD KAVFKINIVP KVNYTIYDGF NLRNTNLAAN FNGQNTEINN MNFTKLKNFT
     GLFEFYKLLC VRGIITSKTK SLDKGYNKAL NDLCIKVNNW DLFFSPSEDN FTNDLNKGEE
     ITSDTNIEAA EENISLDLIQ QYYLTFNFDN EPENISIENL SSDIIGQLEL MPNIERFPNG
     KKYELDKYTM FHYLRAQEFE HGKSRIALTN SVNEALLNPS RVYTFFSSDY VKKVNKATEA
     AMFLGWVEQL VYDFTDETSE VSTTDKIADI TIIIPYIGPA LNIGNMLYKD DFVGALIFSG
     AVILLEFIPE IAIPVLGTFA LVSYIANKVL TVQTIDNALS KRNEKWDEVY KYIVTNWLAK
     VNTQIDLIRK KMKEALENQA EATKAIINYQ YNQYTEEEKN NINFNIDDLS SKLNESINKA
     MININKFLNQ CSVSYLMNSM IPYGVKRLED FDASLKDALL KYIYDNRGTL IGQVDRLKDK
     VNNTLSTDIP FQLSKYVDNQ RLLSTFTEYI KNIINTSILN LRYESNHLID LSRYASKINI
     GSKVNFDPID KNQIQLFNLE SSKIEVILKN AIVYNSMYEN FSTSFWIRIP KYFNSISLNN
     EYTIINCMEN NSGWKVSLNY GEIIWTLQDT QEIKQRVVFK YSQMINISDY INRWIFVTIT
     NNRLNNSKIY INGRLIDQKP ISNLGNIHAS NNIMFKLDGC RDTHRYIWIK YFNLFDKELN
     EKEIKDLYDN QSNSGILKDF WGDYLQYDKP YYMLNLYDPN KYVDVNNVGI RGYMYLKGPR
     GSVMTTNIYL NSSLYRGTKF IIKKYASGNK DNIVRNNDRV YINVVVKNKE YRLATNASQA
     GVEKILSALE IPDVGNLSQV VVMKSKNDQG ITNKCKMNLQ DNNGNDIGFI GFHQFNNIAK
     LVASNWYNRQ IERSSRTLGC SWEFIPVDDG WGERPL
//
